Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal cenegermin for severe pediatric traumatic brain injury
2019-002282-35Phase 2Completed
- Sponsor
- Policlinico Gemelli
- Start
- May 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cenegermin in traumatic brain injury (TBI) and vegetative state (VS), sponsored by Policlinico Gemelli. Primary endpoints: Improvement of clinical and neurological conditions, MRI brain lesion improvement and 2 more. Started May 2021; status: completed.
02
Drugs
cenegermin
03
Conditions
traumatic brain injury (TBI)vegetative state (VS)
Beyond the preview
Go deeper on 2019-002282-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002282-35.